Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 20/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30875927 | 1.00 | TRPV1 (0.72) | TRPV1 | |
| SCHEMBL30875922 | 0.88 | TRPV1 (0.77) | TRPV1 | |
| SCHEMBL3101222 | 0.88 | TRPV1 (0.77) | TRPV1 | |
| SCHEMBL3104060 | 0.84 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL30875924 | 0.84 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL5449613 | 0.83 | TRPV1 (0.69) | TRPV1 | |
| SCHEMBL3089655 | 0.82 | TRPV1 (0.86) | TRPV1 | |
| SCHEMBL3106677 | 0.82 | TRPV1 (0.86) | TRPV1 | |
| SCHEMBL30875920 | 0.82 | TRPV1 (0.86) | TRPV1 | |
| SCHEMBL3104055 | 0.81 | TRPV1 (1.00) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249203-A1 | COMPOUNDS THAT INHIBIT TRPV1 AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | claimed |
| EP-2054390-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPV1 AND USES THEREOF | Abbott Laboratories (US) | 2009-05-06 | — | — | EP | claimed |
| US-20080058401-A1 | 1-(2-(3,3-dimethylbutyl)-4-(trifluoromethyl)benzyl)-3-(1-methyl-1H-indazol-4-yl)urea; transient receptor potential vanilloid-1 (TRPV1) antagonist; low inhibitory activity against drug metabolism enzyme CYP3A4; antinociceptive, analgesic, antiinflammatory, antischemic agent; neuropatic pain | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | claimed |
| WO-2008024945-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPV1 AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-02-28 | — | — | WO | claimed |
| US-20260048008-A1 | ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF | OCULAR THERAPEUTIX INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20210290524-A1 | TOPICAL TRPV1 ANTAGONISTS AND METHODS AND COMPOSITIONS THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-09-23 | — | — | US | disclosed |
| US-8815930-B2 | Compounds that inhibit TRPV1 and uses thereof | ABBVIE INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20100249203-A1 | COMPOUNDS THAT INHIBIT TRPV1 AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-7767705-B2 | 1-(2-(3,3-dimethylbutyl)-4-(trifluoromethyl)benzyl)-3-(1-methyl-1H-indazol-4-yl)urea; transient receptor potential vanilloid-1 (TRPV1) antagonist; low inhibitory activity against drug metabolism enzyme CYP3A4; antinociceptive, analgesic, antiinflammatory, antischemic agent; neuropatic pain | ABBOTT LABORATORIES (US) | 2010-08-03 | — | — | US | disclosed |
| EP-2054390-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPV1 AND USES THEREOF | Abbott Laboratories (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080058401-A1 | 1-(2-(3,3-dimethylbutyl)-4-(trifluoromethyl)benzyl)-3-(1-methyl-1H-indazol-4-yl)urea; transient receptor potential vanilloid-1 (TRPV1) antagonist; low inhibitory activity against drug metabolism enzyme CYP3A4; antinociceptive, analgesic, antiinflammatory, antischemic agent; neuropatic pain | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008024945-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPV1 AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048008-A1 | ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF | KIT, IL33, LY96 | TRPV1 2697/4885 |
| US-20100249203-A1 | COMPOUNDS THAT INHIBIT TRPV1 AND USES THEREOF | TRPV1, TRPV3, TRPA1 | TRPV1 1/4885 |
| US-20080058401-A1 | 1-(2-(3,3-dimethylbutyl)-4-(trifluoromethyl)benzyl)-3-(1-methyl-1H-indazol-4-yl)urea; transient receptor potential vanilloid-1 (TRPV1) antagonist; low inhibitory activity against drug metabolism enzyme CYP3A4; antinociceptive, analgesic, antiinflammatory, antischemic agent; neuropatic pain | TRPV1, TRPA1, OPRK1 | TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.